Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Recruiting now · Not applicable

Conditions studied: Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological, VEGFR-TKI

In brief

The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.

Key facts

Study ID

NCT07124858

Run by

Federation Francophone de Cancerologie Digestive

People needed

300

Starts

2026-03-10

Expected to finish

2031-12-31

Last updated by the study team

2026-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 and over.
• Histologically confirmed colorectal adenocarcinoma with locally advanced disease and/or unresectable metastasis(es) receiving treatment with fruquintinib under i) compassionate/early access and ii) marketing authorisation and reimbursement in France.
• Obtain informed consent from the patient for the clinical-biological cohort.
• Agreement to take biological samples of ctDNA and send tumour blocks (patient participation in the pharmacokinetic study remains optional).

You may not qualify if…

• Patient with another concurrent cancer at the time of diagnosis, requiring systemic treatment or influencing prognosis (in the opinion of the centre's medical team).
• Contraindication due to psychological or social reasons that may hinder follow-up (cognitive deficit, psychological disorders incompatible with obtaining consent; inability to be followed in the same centre throughout the follow-up period for geographical reasons).
• Pregnant or breast-feeding women.
• Patients under court protection or subject to a protective measure (patient under guardianship or curatorship).

Where it is running

• Centre Hospitalier — Albi, France (enrolling)
• CHU — Amiens, France (enrolling)
• Clinique de L Europe — Amiens, France (enrolling)
• Centre Hospitalier — Annecy, France (enrolling)
• Centre Hospitalier — Aurillac, France (enrolling)
• Centre Hospitalier — Bayeux, France (enrolling)
• Centre Hospitalier — Bayonne, France (enrolling)
• Centre Hospitalier — Beauvais, France (enrolling)
• CHU — Besançon, France (enrolling)
• Centre Hospitalier Bethune Beuvry — Beuvry, France (enrolling)
• Centre Pierre Curie — Beuvry, France (enrolling)
• Clinique Tivoli — Bordeaux, France (enrolling)
• Polynclinique Bordeaux Nord Aquitaine — Bordeaux, France (enrolling)
• CHU — Brest, France (enrolling)
• CHU — Caen, France (enrolling)
• Centre Hospitalier — Calais, France (enrolling)
• Infirmerie Protestante — Caluire-et-Cuire, France (enrolling)
• Clinique Sainte Marie — Chalon-sur-Saône, France (enrolling)
• ROC37 — Chambray-lès-Tours, France (enrolling)
• Centre Hospitalier — Chartres, France (enrolling)
• Centre Hospitalier — Cholet, France (enrolling)
• Clinique Sainte Come — Compiègne, France (enrolling)
• Centre Hospitalier Sud Francilien — Corbeil-Essonnes, France (enrolling)
• Clinique Branche - Clinique Flandres — Coudekerque-Branche, France (enrolling)
• Poitiers CHU — Poitiers, France, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.